Clinical Trial Search

Primary: Percentage of Total Sleep Time in Stage 2 Sleep Pre- and Post-study Medication (Stage 2 Percent) — 51.3; 53.8; 50.2; 59.6 percentage of total sleep time

Primary: Mean Reduction Change in Benzodiazepine Use Per Day Based on Time Line Follow Back — 4.0; 2.3 milligrams/day

Primary: Change in Positive Affect and Negative Affect From Baseline to After a 2 Minute Mood Induction — 3.7; 4.63; 1.97; 1.56 units on a scale

Primary: Depressive Symptoms Assessed With the Beck Depression Inventory-II — -4.42; -.650 units on a scale

Primary: Number of Awakenings After Sleep Onset (NAASO) — 39.5; 34.9 Awakenings — p=0.424

Primary: CAPS Recurrent Distressing Dreams Item — -1.9; -1.7 scores on a scale

Primary: Insomnia Severity — 21.58; 12.45 ISI Score

Primary: Center for Epidemiologic Studies-Depression (CES-D) Scale Mean Total Score — 12.96; 18.02; 11.53; 9.43 Units on a scale

Primary: Time to First Drink (Days) — 16.5; 8.0 Days

Primary: Change in Ventral Striatal Activation Occurring in Anticipation of Reward During the Monetary Incentive Delay Task Measured by fMRI — 0.718; 0.331 Z score — p=0.0095

Primary: Follicular Cycle Total Behavioral Score for Calendar of Premenstrual Experiences (COPE) Self Assessment — 3; 5 units on a scale

Primary: Short PTSD Rating Interview (SPRINT) — 16.13; 19.88 units on a scale

Primary: CSF Markers Related to Dementia — 4332.1; 4824.0; 393.2; 419.4 picograms per milliliter

Primary: Sleep Quality Evaluation — 4.63; 11.75 score on a scale

Primary: Change in Timeline Followback of Substance Use (TLFB) — 2.3; 3.3 Days